Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02374814 · ClinicalTrials.gov registry record · Phase 4
Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis
A Phase 4 study of Rabies, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT02374814 is a Phase 4 study of Rabies that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02374814, a Phase 4 study of Rabies, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the effectiveness of a two dose versus a three dose schedule and intramuscular versus intradermal injection for pre-exposure prophylaxis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rabies vaccine
Study Locations (1)
New York
- State University of New York, Upstate Medical University (SUNY-UMU) - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-03-24 |
| Est. Completion | 2016-09-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02374814
The ClinicalTrials.gov registry entry for NCT02374814 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rabies appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02374814 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02374814 about?
NCT02374814 is a clinical study titled "Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis". The purpose of this study is to compare the effectiveness of a two dose versus a three dose schedule and intramuscular versus intradermal injection for pre-exposure prophylaxis.
What is the current status of trial NCT02374814?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2015-03-24. Estimated completion is 2016-09-22.
What conditions does trial NCT02374814 study?
This clinical trial studies the following conditions: Rabies.
What interventions are being tested in trial NCT02374814?
The interventions under investigation include: Placebo (DRUG), Rabies vaccine (DRUG).
Who is sponsoring clinical trial NCT02374814?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02374814 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rabies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.